Affiliation:
1. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India
Abstract
Introduction:
Psoriasis is an incurable, non-contagious inflammatory autoimmune skin disease characterised
by abnormal skin redness and flaky patches on the body surface. It is caused by negative signals produced
by the immune system, leading to excessive growth and differentiation of keratinocytes and other inflammatory
reactions on the skin. The topical route is primarily preferred in treating skin disorders due to the
smaller size of the drug molecule, which allows them to cross the outer layer of the skin, i.e., stratum corneum,
and permeate into the deep layer, unlike transdermal and other routes. The conventional topical treatments used
in the past, such as coal tar and dithranol, lead to meager patient compliance due to decreased potency and imperfect
aesthetic. In contrast, systemic therapy such as methotrexate, cyclosporine, and acitretin produce related
side effects. At present, various novel carriers like liposomes, ethosomes, niosomes, nanostructured lipid carriers,
etc., have shown promising results in the treatment of psoriasis. Therefore, this review primarily concentrates
on the current advancements in novel carriers for various drugs to treat psoriasis topically.
Area covere:
The goal of this review is to provide a comprehensive overview of the pathophysiology, epidemiology,
types, causes, diagnosis, and topical treatment options for psoriasis, as well as the role of nanotechnology-
based delivery systems in psoriasis management.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献